Author name: Claritas Rx

AstraZeneca is experiencing tremendous success and progress under the leadership of CEO Pascal Soriot. His current objective is to achieve a revenue target of $80 billion by 2030. A decade ago, when AstraZeneca was experiencing a period of stagnation, the CEO projected a bold revenue goal of $45 billion by 2023. In a triumphant turn […]

The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering

Tuesday brought good news for asthma sufferers and the healthcare community alike, courtesy of GSK. The pharmaceutical firm announced the successful reduction of annual asthma attacks in two pivotal clinical trials of its experimental antibody treatment named Depemokimab. The trials involved adults and adolescents afflicted with a form of severe asthma. GSK’s newly developed long-lasting

In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with

Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty

The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration

The United States is currently experiencing an unsettling wave of drug shortages, as reported by the American Society of Health-System Pharmacists (ASHP). This ongoing crisis is putting the flexibility and robustness of our healthcare system to the test amid an unparalleled rise in medication shortages. According to the ASHP report, the first three months of

In the realm of healthcare, the patient journey stands as a fundamental framework, guiding the interaction between patients, healthcare providers, and the wider health ecosystem. But within the vast spectrum of patient care, not all journeys are equal. Some are marked by urgency, the relentless pursuit of health, and the stark realities of a life